Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Depreciation & Amortization (CF): 2023-2024

Historic Depreciation & Amortization (CF) for Zenas BioPharma (ZBIO) over the last 2 years, with Dec 2024 value amounting to $137,000.

  • Zenas BioPharma's Depreciation & Amortization (CF) fell 69.44% to $11,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $79,000, marking a year-over-year decrease of 41.04%. This contributed to the annual value of $137,000 for FY2024, which is 21.24% up from last year.
  • Latest data reveals that Zenas BioPharma reported Depreciation & Amortization (CF) of $137,000 as of FY2024, which was up 21.24% from $113,000 recorded in FY2023.
  • In the past 5 years, Zenas BioPharma's Depreciation & Amortization (CF) ranged from a high of $137,000 in FY2024 and a low of $113,000 during FY2023.
  • Its 2-year average for Depreciation & Amortization (CF) is $125,000, with a median of $125,000 in 2023.
  • Data for Zenas BioPharma's Depreciation & Amortization (CF) shows a peak YoY increased of 21.24% (in 2024) over the last 5 years.
  • Over the past 2 years, Zenas BioPharma's Depreciation & Amortization (CF) (Yearly) stood at $113,000 in 2023, then rose by 21.24% to $137,000 in 2024.